BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28349821)

  • 1. LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.
    Wang D; Cao X; Zhang Y; Liu Y; Yao C; Ge W; Xu Y
    Tumour Biol; 2017 Mar; 39(3):1010428317695014. PubMed ID: 28349821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer.
    Nagelkerke A; Mujcic H; Bussink J; Wouters BG; van Laarhoven HW; Sweep FC; Span PN
    Cancer; 2011 Aug; 117(16):3670-81. PubMed ID: 21319150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.
    Zhu L; Feng H; Jin S; Tan M; Gao S; Zhuang H; Hu Z; Wang H; Song Z; Lin B
    Tumour Biol; 2017 Jul; 39(7):1010428317711655. PubMed ID: 28671040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer.
    Kanao H; Enomoto T; Kimura T; Fujita M; Nakashima R; Ueda Y; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Tanigami A; Yoshino K; Murata Y
    Cancer Res; 2005 Oct; 65(19):8640-5. PubMed ID: 16204031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
    Gao GL; Liu LD; Zou XS; Chen WX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.
    Jiang H; Qi L; Wang F; Sun Z; Huang Z; Xi Q
    Int J Mol Med; 2015 May; 35(5):1374-80. PubMed ID: 25812535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
    Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
    Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.
    Niu C; Sun X; Zhang W; Li H; Xu L; Li J; Xu B; Zhang Y
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
    Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
    Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues.
    Sun R; Wang X; Zhu H; Mei H; Wang W; Zhang S; Huang J
    Oncotarget; 2014 Dec; 5(23):12398-409. PubMed ID: 25362357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
    Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
    Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
    Gao C; Yao H; Liu H; Feng Y; Yang Z
    BMC Cancer; 2019 Mar; 19(1):237. PubMed ID: 30876464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
    Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of RRBP1 in epithelial ovarian cancer and its clinical significance.
    Ma J; Ren S; Ding J; Liu S; Zhu J; Ma R; Meng F
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31285390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
    Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
    Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study.
    Ditto A; Martinelli F; Reato C; Kusamura S; Solima E; Fontanelli R; Haeusler E; Raspagliesi F
    Ann Surg Oncol; 2012 Nov; 19(12):3849-55. PubMed ID: 22707110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.